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Abstract
Background: High-throughput RNAi screening is widely applied in biological research, but remains expensive,
infrastructure-intensive and conversion of many assays to HTS applications in microplate format is not feasible.
Results: Here, we describe the optimization of a miniaturized cell spot microarray (CSMA) method, which facilitates
utilization of the transfection microarray technique for disparate RNAi analyses. To promote rapid adaptation of the
method, the concept has been tested with a panel of 92 adherent cell types, including primary human cells. We
demonstrate the method in the systematic screening of 492 GPCR coding genes for impact on growth and
survival of cultured human prostate cancer cells.
Conclusions: The CSMA method facilitates reproducible preparation of highly parallel cell microarrays for large-
scale gene knockdown analyses. This will be critical towards expanding the cell based functional genetic screens to
include more RNAi constructs, allow combinatorial RNAi analyses, multi-parametric phenotypic readouts or
comparative analysis of many different cell types.
Background
High-throughput screening (HTS) of cellular effects of
RNA interference libraries (siRNA or shRNAs) is now
being increasingly applied to explore the role of genes
in specific cell biological processes and disease states.
However, the technology is still limited to specialty
laboratories due to the requirements for robotic infra-
structure, access to expensive reagent libraries, expertise
in HTS assay development, standardization, data analysis
and applications.
Currently, most described systemic-scale RNAi studies
have been performed using microplate based screening
platforms. Due to the high reagent demand of well
based applications, these studies are often restricted to
the analysis of a single parameter [1-3], cell morphology
[4,5] or reporter gene assays [6-8] at a time. Though
well suited for specific biological questions, this provides
a restricted view on cell biology and furthermore, many
informative assays cannot be converted to HTS format
in microplate based platforms due to methodological
limitations or cost considerations. In the future, a signif-
icant increase in the platform flexibility and decrease in
screening costs will be required to expand functional
large-scale screens to include more RNAi constructs,
allow combinatorial siRNA analyses (e.g. gene-gene,
gene-drug or gene-condition interaction), multi-para-
metric phenotypic readouts or comparative analysis of
many different cell types. Such comprehensive perturba-
tion of gene networks in cells will be critical towards
understanding of cell and cancer biology as well as the
discovery of novel therapeutic opportunities.
The transfection cell microarray technology has been
proposed as a new platform for large-scale RNAi ana-
lyses allowing significant increase in experiment
throughput and reduction in screening costs. The initial
publication of transfection cell microarrays described
reverse transfection of cDNAs to adherent cells [9].
Cells were grown as a uniformc a r p e to v e rap r i n t e d
microarray consisting of cDNA expression constructs
and lipid transfection reagent resulting in the overex-
pression of the target genes in living cells. The concept
was then adapted to RNAi analysis with description of
cell carpet arrays for transfection of synthetic siRNAs to
adherent cells [10,11]. After these primary publications,
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application of different types of cell microarray methods
[12-20]. For example, these methods have been used
extensively to investigate cell cycle in human cancer
cells [21]. Though the cell microarrays have slowly
evolved to become a more widely accepted screening
technology, in many publications, the individual arrays
have contained only a modest number of samples, and
data from multiple small arrays have been combined for
large-scale coverage due to technological limitations of
the methods [16,20,21].
Here, we describe the optimization of a cell spot
microarray (CSMA) method with the future systemic-
scale research needs in mind. The method provides a
patterned array platform with spatially confined cell
spots that allow simple production of cell microarrays
with significantly increased sample coverage in micro-
plate-sized array plates readily compatible with standard
imaging instruments. The confined cell spot pattern also
facilitates automated imaging and analysis of the arrays
with multiparametric assays otherwise difficult or non-
feasible in HTS. To allow rapid adaptation of the techni-
que we optimized an application protocol of the CSMA
cell patterning method for 85 cell types and applied the
platform for functional genetics profiling of G-protein
coupled receptor coding genes in cultured prostate can-
cer cells and non-malignant epithelial prostate cells,
demonstrating the potential of the CSMAs for context
specific target discovery.
Results
Cell spot microarray method
In the CSMA method siRNA samples complexed with
lipid transfection agent and extracellular matrix compo-
nents are microarrayed with contact printing to a micro-
plate sized array plate with a hydrophobic polystyrene
surface (Figure 1A). Adherent cells are dispersed over the
array as suspension and allowed to adhere for a short
period, commonly 5 to 15 minutes before unadhered
cells, unable to make permanent contact onto the array
background during the initial adherence incubation, are
washed off. After the wash step cells are left growing only
on the spatially confined spots, providing a platform
compatible for ultra-high sample densities and simplified
imaging and quantification of cells on the siRNA spots
(Figure 1B). As the patterning of adhesion promoting
siRNA-matrix samples onto the arrays is done with con-
tact printing the diameter of array spots and hence num-
ber of cells per spot can be controlled with printing pin
diameter. Number of cells per spot is though dependent
on the characteristics and growth properties of the cells.
With epithelial derived PC-3 prostate cancer cells, num-
ber of cells on 200 μm spots following 48 h culture was
51 ± 3 (s.d., replicate spots n = 100) and 151 ± 8 on 400
μm spots. With primary un-immortalized prostate stro-
mal cells, number of cells on 200 μm spots was 21 ± 6 (s.
d., n = 192 spots) (Figure 1C). A microscopic 72 h time-
lapse imaging of PC-3 cells growing on a 200 μmC S M A
spot (Figure 1D and Additional file 1) indicates how cells
continue to prefer the printed matrix surface for their
growth for several days.
Due to the high precision of contact microarray print-
ing the method can be scaled for ultra-high sample densi-
ties. With 200 μm array spots and 500 μms p o ts p a c i n g ,
arrays with 3,888 spots in an area of 18 × 54 mm or
15,552 spots in a single microplate-sized vessel with four
large rectangular wells could be printed (Figure 2A) [22].
To achieve an array format compatible with majority of
commonly used adherent cell types, different array sur-
face materials were tested in combinations with different
ECM protein coatings, cell dissociation procedures and
adhesion incubation times for different cell types. Array-
ing of Matrigel ECM mixture onto a polystyrene surface
with a hydrophobic surface charge was found to facilitate
spatially restricted adhesion of majority of tested cell
types (92%, 85/92) (Figure 2B). Although untreated poly-
styrene is not cell-repellent and cells are eventually able
to adhere also to the array background, use of a non-
enzymatic cell dissociation reagent and restricted cell
adhesion time was found to significantly enhance spatial
adherence of all tested cell types onto the array spots
over the plain plastic background. With VCaP prostate
cancer cells, the incubation time required for adhesion of
cells to CSMA spots was shortened by 48-fold in com-
parison to the trypsin based cell dissociation technique
(15 min vs. 12 h). Since the same array spot composition
supported adhesion and growth of majority of tested cell
types it was only necessary to optimize the cell dissocia-
tion method and adhesion time for each cell type [Addi-
tional file 2].
siRNA reverse transfection on CSMAs
To establish lipid based siRNA reverse transfection on
cell spot microarrays, we aimed for low siRNA and lipid
concentrations in order to suppress potential lipid toxi-
city and off-target effects. Efficacy of siRNA transfection
on CSMAs was tested by printing 200 μm array spots
from 10-30 ng/μl siRNA samples [19]. Efficacy of target
silencing was evaluated with U-2OS sarcoma cells
expressing a destabilized TurboGFP (TuGFP). Cells
were transfected for 72 h on an array with 25 print
replicates of a validated TuGFP siRNA in three concen-
trations (Figure 3A). TuGFP signal intensity was ana-
lyzed using automated microscopic analysis. With
normalization of the cytoplasmic TuGFP signal to the
nuclear DNA counterstaining (Figure 3B) of the cells, an
up to 60% efficacy was measured with the lowest 10 ng/
μl siRNA concentration (P = 3.7E-06) across all replicate
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Figure 1 Principle of the cell spot microarray (CSMA) method. (A) CSMA work flow: siRNA samples in a printing solution containing
transfection lipid and extra-cellular matrix proteins are robotically printed on a hydrophobic polystyrene surface. A suspension of adherent cells
is allowed to adhere onto the array spots, followed by washing un-adhered cells off, leaving adhered cells only to printed array positions. After
reverse transfection for a selected time, the arrays are stained using e.g. traditional multi-label immunostaining protocols for high content image
analysis of multiple parameters. (B) CSMA method allows production of high density patterned cell arrays. Left panel displays a microarray
scanned view of 200 μm cell spots with 500 μm spot spacing. Scale bar 0,5 mm. Right panel: Due to the spatially confined layout of the spots,
automated imaging and segmentation of cells on CSMA spots can be performed using automated image analysis software. Scale bar 200 μm.
(C) Microscopic image and microarray scanned view of 200 μm CSMA spots (Top left panel;i) and 400 μm spots (Top right;ii) of PC-3 cells
stained for DNA (blue) and F-Actin (green) after 48 h culture. Microscopic image and microarray scanned view of 200 μm CSMA spots (Bottom;
iii) of primary prostate stromal cells cultured for 48 h and stained for DNA (blue) and F-Actin (green). Scale bar 900 μm. (D) Phase contrast
microscopic images from a timelapse series of PC-3 cells cultured on 200 μm array spots for 72 h.
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Page 3 of 14transfections, an over 70% efficiency was achieved with
20 ng/μl siRNA samples (P = 1.7E-08) and an up to
90% silencing efficacy was achieved with the 30 ng/μl
siRNA samples (P = 1.2E-10). To evaluate specificity of
the siRNA induced effects, an identical array of a vali-
dated siRNA for CDC2 (CDK1, cyclin-dependent kinase
1) was used as a control for the TuGFP analysis (Figure
3A). With comparative image based cytometry analysis
of the siCDC2 transfected cells (Figure 3C) and the
TuGFP transfected cells, the CDC2 inhibition was found
to induce a prominent G2 cell cycle arrest with 51.1% of
cells in G2 after 72 h transfection with the 10ng/μl
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Figure 2 Preparation of high density cell microarrays with multiple cell types using CSMA method. (A) Laser microarray scanned
composite image of VCaP prostate cancer cells cultured for 72 h on a four welled CSMA plate with 15,552 siRNAs spots (200 μm) printed as
four sub-arrays with 3,888 spots in 18 mm × 54 mm areas. Magnified images of the array displaying the parallel staining of the cells for DNA, F-
Actin, Ki-67 and cleaved PARP. Scale bar 18 mm. (B) Microscope images of 200 μm diameter array spots with: (1-12) VCaP, OVCAR-8, Caco-2, 3T3,
PC-3, T-98G, KPL-4, primary prostate stromal cells, HEK-293, HeLa, SAOS-2 and primary osteosarcoma cells cultured on CSMAs for 48 h and
stained with multiple types of immunostainings. Scale bar 100 μm.
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Figure 3 siRNA reverse transfection on CSMAs. (A) siRNA mediated gene silencing on CSMA was tested with U-2OS sarcoma cells expressing
a destabilized TurboGFP. Silencing efficacy of different siRNA concentrations was compared with negative control siRNA and a control siRNA for
CDC2. Composite (TuGFP = green, DNA = blue) and single channel confocal laser microarray scanned images of a U-2OS array with three 25
replicate spot sub-grids of siTuGFP and siCDC2 and two control siRNA sub-grids. Scale bar 2 mm. (B) Top: Automated image analysis was used
to segment nuclei of individual cells and fixed area spanning 15 pixels outside nucleus was used to measure the cytoplasmic signal for TuGFP.
Middle: 20× microscopic images of control siRNA (UL) and TuGFP siRNA spots (UR = 10 ng/μl, LL = 20 ng/μl, LR = 30 ng/μl). Quantification of
cytoplasmic TuGFP against nuclear DAPI intensity indicated an up to 90% transfection efficacy with 30 ng/μl siRNA. Scale bar 100 μm. (C) Top:
Image based cytometry analysis of integrated nuclear DAPI intensity (nuclear area/DAPI mean intensity) was used for cell cycle analysis of siCDC2
and siTuGFP transfected cells. Coloured boxes indicate cells classified as G1-S (red), G2 (Blue) and M (purple). Inhibition of CDC2 induced a
prominent G2 arrest with all siRNA concentrations in comparison to control or TuGFP. (D) Top: Microarray scanned images of a CSMA with PC-3
cells stained for ITGA5 and ITGB1 following 48 h transfection with control and ITGA5 siRNA. Top right: Based on microscopic image analysis of
ITGA5 signal against DAPI counterstaining of the cells, an up to 75% knockdown was achieved across the 25 replicates with 20 ng/μl ITGA5
siRNA. Bottom: 20× microscopic images of the control and ITGA5 siRNA spots. Scale bar 2 mm and 100 μm.
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Page 5 of 14siRNA (P = .0003), 49.8% with 20 ng/μls i R N A( P=
3.8E-05) and 50.6% with 30 ng/μl siRNA (P = 0.0006) in
comparison to the 28.2% of cells in G2 in the control
transfections (Figure 3C). Transfection with the TuGFP
siRNA had an insignificant effect on the cell cycle distri-
bution with all the siRNA concentration (Figure 3C).
Silencing of an endogenous target gene was evaluated
with antibody based immunofluorescence detection of
integrin alpha-5 (ITGA5) in PC-3 prostate cancer cells
transfected for 48 h on a CSMA with replicate spots of
a validated ITGA5 siRNA. Here, an up to 75% average
silencing efficacy was measured from 25 replicate trans-
fections with 30 ng/μl siRNA (P = 3.04E-08) (Figure
3D). Endogenous target silencing was further evaluated
with antibody based detection of calpain 2 (CAPN2)
silencing on VCaP prostate cancer cells transfected for
72 h on a CSMA with 96 technical replicates of four dif-
ferent CAPN2 and control siRNAs [Additional file 3:
Supplemental Fig. S1A]. Based on confocal microarray
laser scanning analysis of the cumulative spot level
CAPN2 staining intensity against DNA counterstaining
of the cells [Additional file 3: Supplemental Fig. S1B], a
mean transfection efficacy of 31 to 94% silencing per
siRNA construct was achieved in comparison to the
negative control siRNA transfected cells, using 10 ng/μl
siRNA concentration. For the most efficient CAPN2
siRNA (SI03057306), the inter-spot efficacy CV between
all the replicate spots was 6.6%. To evaluate that the
detected variation of the siRNA construct efficacy was
independent of the transfection method, VCaP cells
were transfected in conventional 96-wells for 72 h and
analyzed with Western blot. An identical efficacy profile
for the CAPN2 siRNA constructs was identified [Addi-
tional file 3: Supplemental Fig. S1C] thus highlighting
the dependency of siRNA mediated gene silencing on
the siRNA construct specificity. To further validate the
transfection efficacy with VCaP cells we performed a
Western blot analysis of cells transfected for 72 h on an
array with 384 (200 μm) replicate spots of the most
effective CAPN2 siRNA and an identical array of nega-
tive control siRNA. Here, an up to 85% silencing efficacy
was achieved, verifying the immunofluorescence
detected high transfection efficacy. In comparison, an
identical assay using PC-3 prostate cancer cells and
SVpgC2a immortalized primary oral keratinocyte cells
(Kindly provided by Prof. Roland Grafström) indicated
an up to 90 and 65% transfection efficacy (respectively)
[Additional file 3: Supplemental Fig. S1D].
Application of the CSMA method for systematic
functional genetics analyses
To validate the compatibility of the CSMA method in
systematic RNAi screening we established an assay for
analysis of G-protein coupled receptor (GPCR) coding
genes impacting on the growth and survival of cultured
prostate cells. A siRNA library with two siRNA con-
structs against 492 human GPCRs and replicate negative
control siRNA samples was used for preparation of
arrays used for parallel analysis of GPCRs important for
growth of androgen responsive VCaP and LAPC-4 pros-
tate cancer cells and RWPE-1 non-malignant prostate
epithelial cells. To allow microscopic detection of RNAi
effects impacting cell proliferation and survival, we
established an antibody based assay for detection of Ki-
67 as a proliferation marker and cleaved PARP (poly
(ADP-ribose) polymerase) as an apoptosis marker. The
markers show a mutually exclusive staining pattern
allowing simple phenotypic delineation of proliferating
and apoptotic cells on basis of the nuclear staining
intensity of the proteins against DNA counterstaining of
the cells (Figure 4A &4B). The Ki-67 protein is detected
abundantly in the nucleus surrounding the chromatin in
all phases of active cell cycle with an increasing intensity
from G1 to M, whereas PARP is cleaved in response to
induction of apoptosis resulting in increasing cPARP
level from the early events of apoptosis induction to for-
mation of apoptotic bodies (Figure 4A).
For the screening two identical arrays with random
order printed individual siRNA samples were used to
transfect each cell type for 48 h followed with immuno-
fluorescent staining of the cells for analysis using auto-
mated microscopic imaging (Olympus scanR). Each
array position was imaged using a long aperture
LUCPLFLN x20 objective and automated image analysis
software (Olympus scanR) was used to segment the cells
and analyze the nuclear staining intensities of the two
antibodies (Figure 4B). The spot level ratio of RNAi
induced changes in the cumulative nuclear intensities of
Ki-67 and cPARP was used to identify target genes caus-
ing inhibition of cell proliferation and induction of
apoptosis upon silencing. By comparison of the scored
results of the two replicate arrays for each cell type, the
CSMA experiments displayed a statistically significant
concordance with Pearson correlations between r = 0.79
to 0.84 (Figure 4C &4D). For stringent identification of
genes having the most consistent impact on growth and
survival of the analyzed cell lines, results of the replicate
experiments were combined and siRNAs having a z-
score greater than ± 2 s.d. for the measured Ki-67/
cPARP signal ratio over both experiments were consid-
ered significant (Figure 4D and Additional file 4).
In silico transcriptomics validation
To address the in vivo significance of the highlighted
GPCRs in clinical prostate cancer samples, we carried
out a bioinformatic meta-analysis of the clinical expres-
sion profiles of the corresponding genes at the mRNA
level from the publicly available GeneSapiens gene
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Figure 4 Functional RNAi profiling of GPCR coding genes with prostate cell lines. (A) An antibody based assay for detection of nuclear Ki-
67 and cleaved PARP was used for microscopic analysis of cell proliferation and induction of apoptosis (blue = DNA, red = cPARP, green = Ki-
67). In comparison to DNA counterstaining the nuclear intensity for Ki-67 staining increases linearly from G1 to M cell cycle phase whereas the
staining for cPARP increases similarly from induction of apoptosis to formation of apoptotic bodies. (B) For the analysis each array position was
imaged using x20 objective. Cells were segmented on basis of DAPI counterstaining and the intensities of Ki-67 and cPARP were measured from
the nuclear area. On the whole array level the markers displayed a mutually exclusive staining pattern (Bottom left) allowing robust delineation
of proliferating and apoptotic cells (Bottom right). The green and red rectangles on the image display the gated populations of Ki-67 or cPARP
positive cells respectively. (C) Hierarchical partitioning around medoids (PAM) clustering of the standardized (z-score) results of the two biological
replicate CSMA experiments with LAPC-4, RWPE-1 and VCaP cells. (D) Top left: Scatter plot distribution of the replicate experiment z-score results
for LAPC-4 cells. Top right and bottom: Line graph distribution of the combined replicate experiment results for each siRNA construct for the
analyzed cell lines. SiRNAs inducing a greater than ± 2 z-score (displayed in red) were considered significant. Distribution of the negative control
siRNAs shown in green.
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To evaluate potential prostate specificity of the analyzed
GPCRs, we first compared the median expression levels
of the genes in healthy prostate (n = 147) and prostate
cancer samples (n = 349) with the normalized expres-
sion levels of the genes across over 10,000 clinically
annotated tissue samples from other major anatomical
tissue types. Here, seven genes; OPRK1, OR51E1,
OR51E2, GPR160, NPY, CHRM1 and EDG7 displayed
increased expression in prostatic samples in comparison
to other tissue types [Additional file 5]. To identify
genes displaying outlier expression patterns in clinical
prostate cancer samples we calculated an outlier expres-
sion score [24] for the genes by comparing the median
expression levels of the genes in prostate cancer samples
over the healthy prostate control samples [Additional
file 6]. Out of the 492 GPCRs analyzed in the CSMA
experiment, 9 were identified to display an increased
expression pattern in the prostate cancer samples (Fig-
ure 5A). To identify correlations between the in vivo
prostate cancer specificity and the loss-of-function
impact of the genes on the prostate cell lines, the outlier
expression scores were combined with the summarized
CSMA results for the corresponding genes. NPY (neuro-
peptide Y) and GPR160 (G protein-coupled receptor
160) [Additional file 7] were among GPCRs with the
highest prostatic tissue level and prostate cancer specifi-
city index. With analysis of the CSMA results on basis
of rank product analysis [25] of all the three cell lines,
NPY was identified as the strongest common growth
inhibitory siRNA hit in all the three cell lines (Figure
5B), while GPR160 had the strongest growth inhibitory
effect on the cancer cell lines VCaP and LAPC-4, and
an insignificant effect on the RWPE-1 epithelial cells
(Figure 5B-5C), coupling with its overexpression in clini-
cal prostate cancer samples in the Genesapiens database
analysis (p = 3.10E-05, t-Test -5.749) [Additional file 5].
High level in vivo expression of the GPR160 protein was
also identified in clinical prostate cancer specimens in a
public tissue protein profiling database (http://www.pro-
teinatlas.org, [26]) [Additional file 8: Supplemental Fig.
S4A] and a separate previously published transcrip-
tomics analysis [27] of 40 human prostate cancer sam-
ples (p = 2.22E-04, fold change 3.246).
Validation of the screening results
To validate the growth inhibitory knockdown effect of
the two highlighted GPCR coding genes (NPY and
GPR160) a series of secondary validation experiments
were performed. The efficacy of the GPR160 and NPY
siRNAs was validated at the mRNA level in VCaP cells
by means of quantitative RT-PCR [Additional file 8:
Supplemental Fig. S4B]. By comparison of the mRNA
expression level of GPR160 and NPY in the analyzed
cell lines and six additional prostate cancer cell lines
http://www.genesapiens.org, VCaP cells were identified
with the highest expression of both two genes in com-
parison to LAPC-4 and RWPE-1 cells (Figure 5D). To
validate the growth inhibitory effect detected in the
CSMA analysis, we used an enzyme activity based
fluorometric cell viability assay and a panel of prostate
cancer cell lines to verify the effect. Five prostate cell
lines; VCaP, 22Rv1, LAPC-4, PC-3 and RWPE-1 were
transfected in conventional 96-wells for 72 h and
assayed with a fluorescence plate reader. A significant
reduction of cell viability (p < .01) by inhibition of NPY
was measured for all three cell lines included in the
CSMA analysis. Silencing of GPR160 was found to
decrease viability of VCaP and LAPC-4 (p < .01) cells
and moderately the viability of PC-3 prostate cancer
cells (p < .05), but not RWPE-1 (Figure 5E), thus vali-
dating the rank product analysis based CSMA results.
Even though siRNAs for NPY and GPR160 did not
exceed the used -2 s.d. threshold in the primary CSMA
analysis of LAPC-4 cells, they both scored in the valida-
tion assay. A possible reason for the difference in the
results is the difference of the two assay readouts. The
antibody based readout potentially reflect also the apop-
totic mechanism, whereas the fluorometric assay is
dependent solely on the number of viable cells indepen-
dent of underlying mechanisms resulting in the cell kill-
ing. By viewing the resulting phenotype of LAPC-4 cells
(Figure 5C) following GPR160 silencing, a residual stain-
ing for Ki-67 is detected along with an increased stain-
ing for cPARP thus resulting in a smaller signal ratio
than with e.g. the distinct decreased Ki-67 and increased
cPARP signal ratio in VCaPs (Figure 5C). It is also pos-
sible that in the CSMA format apoptotic cells become
detached from the array spots before the staining thus
not scoring in this analysis setting.
Discussion
We describe here the optimization and functional appli-
cation of a miniaturized cell spot microarray (CSMA)
method for RNAi screening. The technique has several
advantages as compared to conventional HTS screening
in microplate format and enhancements also applicable
to previously described cell microarray technologies.
Most importantly, miniaturized high density transfection
microarrays provide an affordable platform for large-
scale cell biological studies. The described CSMAs pro-
vide a method for production of transfection cell arrays
with sample densities allowing screening of up to 15,000
siRNA molecules in a single array plate. Consumption
of the siRNAs and detection reagents in the CSMA
technique is over 200-fold less than with traditional
HTS in 384-well plates (10 ng siRNA/well vs. 50 pg/
spot). Immunofluorescent staining of CSMAs can be
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Page 9 of 14accomplished under a coverslip reducing antibody con-
sumption up to 400-fold as compared to 384-well for-
mat (10 μl antibody dilution per 384 well vs. 320 μlp e r
array plate with 15,552 siRNA samples). Therefore, it is
possible to develop sophisticated HTS assays that would
otherwise not be feasible, and easily convert almost any
cytochemical staining to a HTS assay.
As compared to most of the cell microarray methods,
where a carpet of cells is laid across the whole array
[9-12,14-17,19-21], the CSMA method provides a sim-
plified protocol for achieving a patterned array layout,
where cells only adhere to the sample spots. This con-
figuration facilitates the quality control and digital
image analysis of the cell arrays as cells included in the
analysis can be defined without possibility for sample
mixing between array positions. With future develop-
ment of higher capacity timelapse microscopic imagers,
this platform could also be used for high-throughput
timelapse microscopic analyses.
Since in the method cells are seeded over the entire array
at a time and the spot diameter is limiting the number of
cells adhering to the spots, well-to-well variability inherent
in classical HTS systems is reduced in CSMAs, potentially
increasing the accuracy of the screens. Furthermore, the
arrays are simple to produce and applicable to various
commercially available polystyrene cell culture vessel for-
mats and moreover scalable, limited only by the microarray
printing capacity and throughput of the image analysis sys-
tems. The confined cell spot arrays were accomplished by
including in the printing mixture matrix proteins, which
were deposited on a standard untreated hydrophobic poly-
styrene surface. In addition to promoting cell adhesion, the
ECM matrix proteins have been shown to enhance lipid
based reverse transfection through promotion of cell
spreading and activation of endocytotic pathways in adher-
ent cells, hence yielding an enhanced transfection efficacy
[28-30]. 92 different cell types, including human primary
cells, were tested with the approach and an application
protocol was optimized for 85 cell lines which could be
successfully seeded and cultured on the arrays.
Conclusions
The biological application utilized here to demonstrate
the use of CSMAs for systematic RNAi screening, was
the functional analysis for GPCR coding genes impact-
ing growth and survival of prostate epithelial and pros-
tate cancer cells. With the analysis we demonstrated
that the CSMAs allow robust functional analysis of large
siRNA sets using multiplexed assays, such as the anti-
body based assays and different cell types. The targets
identified based on the integrated analysis of CSMA
data and publicly available transcriptomics data dis-
played high context specificity suggesting GPR160 and
N P Yl i k e l yt ob et h et w om o s ti m p o r t a n tG P C R s
impacting on growth of human prostate and specifically
prostate cancer cells. While these genes have been pre-
viously associated with prostate cancer [31,32], this is
the first comparative functional screening of the GPCR
knockdown phenotypes in different cultured prostate
cell lines, combined with the bioinformatic analysis of
their relative expression levels in prostate tumor sam-
ples. Furthermore, several genes including FZD4,
OPRK1 and OXTR identified here with a growth inhibi-
tory loss-of-function impact on the prostate cancer cells
have been recently associated in independent studies
with a role in prostate cancer pathogenesis [33-35]. This
illustrates the use of CSMA method in the integrated
functional genomics analysis of in vitro RNAi data and
in vivo clinical gene expression data, to quickly nomi-
nate biologically and clinically relevant candidate genes
and potential drug targets for further analysis.
Methods
CSMA printing
The matrix-siRNA samples used for array printing were
prepared to U-bottom 384 wells (Ab1055, Abgene) with
a Hamilton STAR 96-channel liquid handling robot
(Hamilton Robotics) in sterile conditions. For each sam-
ple 5 μlo f1 . 6 7μM( f i n a l1 0n g / μl), 3.35 μM (20 ng/μl)
or 5 μM( 3 0n g / μl) siRNA (Qiagen) stock diluted in
OptiMEM-I (Gibco) was mixed with 0.8 μl, 1 μlo r1 . 2
μl (respectively) of siLentFect (Bio-Rad) transfection
agent and 0.2 μl of OptiMEM I. Solutions were incu-
bated for 25 min at RT and mixed with 2 μlo fg r o w t h
factor reduced Matrigel (BD Biosciences) and 2 μlo fi c e
cold OptiMEM-I supplemented with 65 mM of sucrose,
mixed by vortex shaking, centrifuged at 2.000 rpm for 1
min and snap-frozen at -80°C. Source plates were stored
at -20°C between uses. Microarray printing was per-
formed with a Genetix Qarray2 (Genetix Ltd) microar-
ray printer using 16 solid tip pins with 200 μmt i p
(PointTechnologies). Arrays were printed onto clear
untreated polystyrene microplates with four rectangular
wells (Nunc). Printing was done in controlled 55% air
humidity and source plates were kept at +15°C during
printing. To minimize sample carry-over during the
multi-sample print processes a five step distilled water
rinsing (3 × 2.5 seconds and 2 × 5 s) of printing pins
was used followed with 80% ethanol and air drying.
Printed array plates were sealed in airtight bags and
stored at room temperature before use.
siRNA libraries and plasmids
All siRNAs used for the experiments were purchased
from Qiagen. CSMA arrays used for GPCR analysis cov-
ered a library with 2 individual constructs against 492
human GPCR coding genes (GPCR subset of Qiagen
human genome-wide siRNA library v1.0). All arrays
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cate negative control siRNA positions equivalent to 5%
of all targeting siRNAs on the array (All star negative
control, Qiagen 1027280). SiRNA identifiers (Qiagen)
for CAPN2, GPR160 and NPY are provided in Figure 3
and 5, TuGFP siRNA (1027020), CDC2 (1027273) and
ITGA5 (SI02654841). Plasmid for expression of Tur-
boGFP in U-2OS cells was purchased from Evrogen
(pTurboGFP-dest1 vector, cat.# FP519).
Cell culture
All cell lines used for the testing of the CSMA method
were cultured according to the protocols recommended
for the cell line. U-2OS, VCaP, LAPC-4 and 22RV1
cells (ATCC, Manassos, USA) were grown in RPMI-
1640 (Gibco) supplemented with 10% FBS, 10 μg/ml
penicillin and streptomycin and 2 mM L-glutamine.
RWPE-1 (ATCC, Manassos, USA) cells were grown in
Keratinocyte Serum Free Medium (K-SFM, Gibco) sup-
plemented with 0.05 mg/ml BPE (bovine pituitary
extract) and 5 ng/ml EGF. PC-3 cells (ATCC, Manassos,
USA) were grown in F-12K medium (Gibco) supple-
mented with 10% FBS, 10 μg/ml penicillin and strepto-
mycin, and 2 mM L-glutamine. Turbo-GFP expressing
U-2OS cells were established using Fugene HD (Pro-
mega) transfections reagent according to the instruc-
tions provided by the manufacturer. Cells were kept
under G418 (Sigma-Aldrich) selection for 6 passages
prior to assays.
Preparing cells for CSMAs
To allow maximally confined growth of cells on the
CSMA spots, specific cell dissociation and array adhe-
sion protocols were developed. The protocol for VCaP
cells can be used as a guideline for all other tested
cell types. For the CSMA experiments, VCaP cells
were grown to 80% confluence on 10 cm culture
dishes and dissociated with HyQtase (HyClone) treat-
ment for 5 minutes. Conditioned culture medium was
collected from the dish and after dissociation; cells
were re-suspended back to this and pipetted thor-
oughly to achieve a uniform single cell suspension.
For experiments on the four well array plates, 2.5 ×
10^6 cells in 4.5 ml of medium was added carefully to
any corner of a single well, while avoiding application
of cells directly onto the printed array surface and dis-
p e r s e du n i f o r m l yo v e rt h ew h o l ea r r a ys u r f a c e .C e l l s
were allowed to adhere to the arrays at +37°C, 5%
CO2 for 15 min after which excess un-adhered cells
were washed off by gently rinsing the arrays with PBS
until all un-adhered cells were removed. For the trans-
fection, 4.5 ml of fresh normal culture medium was
added to array wells.
Immunofluorescence staining
Immunofluorescence staining of the arrays was per-
formed using standard procedures. Cells were fixed with
2% paraformaldehyde solution for 15 min, permeabilized
with 0.3% Triton-X100 in PBS and the background was
blocked with 2% BSA in PBS before staining with pri-
mary and secondary antibodies. Primary antibodies for
ITGA5 (1:200, rabbit anti-ITGA5 clone 1949, Millipore),
CAPN2 (1:250, rabbit anti-CAPN2, Abcam), cPARP
(1:300, mouse anti-cPARP, Cell Signalling Technologies)
and Ki-67 (1:300, rabbit anti-Ki67, Abcam) were diluted
in blocking buffer and incubated for 60 min at room
temperature, 80 μl per array under a coverslip. Second-
ary labelling antibodies; goat-anti-mouse and donkey-
anti-rabbit conjugated with Alexa488 and -647 dyes
(1:300, Molecular Probes, Invitrogen) were diluted in
blocking buffer and incubated for 60 min at RT. 1 μg/
ml 4’,6-Diamidino-2-phenylindole (DAPI, Invitrogen)
was added to secondary antibody solution for DNA
staining. After secondary labelling, CSMAs plates were
rinsed with distilled H2O, air dried and stored at room
temperature protected from light before imaging.
Microscopic imaging and data analysis
CSMA analysis was performed with microsopic imaging
of the arrays using scanR high content imager (Olympus)
equipped with a Hamamatsu ORCA-ER CCD digital
camera (Hamamatsu Photonics K.K.). Each array spot
was imaged individually with a x20, LUCPLFLN NA 0.40
objective using specific filter sets for DAPI, Alexa488 and
Alexa647 (Semrock, Inc). Acquired images were analyzed
using the scanR image analysis software. Cells on spots
were segmented on the basis of the DNA counterstaining
(Figure 1B) and the nuclear fluorescence intensities for
DAPI, Ki-67 and cPARP were measured. Cells residing
outside the main spot perimeter were excluded from the
analysis on basis of x-y coordinates from the center of
spot. Raw intensities of stains for all cells per spot were
spatially normalized using pin normalization. Ki-67 and
cPARP values were then used to calculate a Ki-67/cPARP
ratio normalized against the DAPI counterstaining per
spot. After normalization, a z-score was calculated for
scoring of the measured spot level values using global
array mean and standard deviation within all samples in
the array. From the analysis, siRNAs with z-scores less
than -2 s.d. or greater than +2 s.d. were considered signif-
icant and the consistency of the siRNA effects across all
measurements or alternative impact on the cancerous
cell lines (VCaP and LAPC-4) in comparison to the
epithelial cells (RWPE-1) was performed using the rank
product approach [25]. The partitioning around medoids
method and the R statistical programming language was
employed for hierarchical clustering of the data.
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datasets
The analysis of in vivo significance of the identified
siRNA targets was based on analysis of public Affymetrix
transcriptome data of prostate samples derived from the
GeneSapiens database [23] using the GTI method as pre-
viously described [24]. The included data was acquired
from multiple public repositories such as 1. The Gene
Expression Omnibus (GEO); GSE1133, GSE1431,
GSE2109, GSE2361, GSE2443, GSE3325, GSE3526,
GSE5258, GSE6606, GSE6608, GSE6919 and GSE96. 2.
The Human Genome Expression Index (HuGEIndex);
HIE01. 3. The Broad Institute Cancer Program Data Sets;
MTE05, MTE10, MTE11 and 4. The NIH-NCI Gene
Expression Data Portal (GEDP); NCE279.
Quantitative RT-PCR and Western blot analysis
For quantitative reverse transcription-PCR (qRT-PCR)
analysis the total cellular RNA was isolated using Trizol
reagent (Invitrogen). For cDNA synthesis, 200 ng of
total RNA was reverse transcribed with the High Capa-
city cDNA Reverse Transcription kit (Applied Biosys-
tems). The cDNA was diluted 1/10 and the Taqman
qRT-PCR analysis was performed with an Applied Bio-
systems 7900HT instrument, using primers designed by
the Universal Probe Library Assay Design Center
(Roche) for NPY; forward CGCTGCGACACTACAT-
CAAC and reverse CTCTGGGCTGGATCGTTTT, and
for GPR160; forward GCATTCAGAGTTACTGG
CTGTC and reverse CCCAACAGGTTATGAAAGC-
TACA. The fluorescent Taqman probes were obtained
from Roche Human Probe Library. Results were ana-
lyzed using SDS 2.3 and RQ manager software (Applied
Biosystems), and the relative expression of mRNA was
determined using beta-actin (forward CCAACCGCGA-
GAAGATGA, reverse CCAGAGGCGTACAGGGA-
TAG) as an endogenous control. The data from two
separate biological experiments, with triplicate samples
was combined. For western blot analysis aliquots of total
cell lysates were fractionated on SDS-polyacrylamide
gels and transferred to nitrocellulose membrane (What-
man Inc). The filters were blocked against non-specific
binding using 5% skim milk. Membranes were probed
with antibodies o/n at +4°C (CAPN2; 1:1000, Abcam).
Equal loading was confirmed by probing the same filter
with a specific antibody for tubulin (1:5000, Abcam).
Signals were revealed by incubating the filters with
horseradish peroxidase-coupled goat anti-mouse IgG
secondary antibody and goat anti-rabbit (1:1000; Sigma)
antibody.
Conventional siRNA transfections and cell viability assay
Validation of target silencing and assaying the effect of
NPY and GPR160 siRNAs on the growth of prostate
cancer cells was performed in clear-bottom 96-well
(2000 cell per well) and 24-well (5 × 10^4 cells per
well) plates. The transfections were made with 10 nM
siRNA constructs (Qiagen) using siLentFect transfec-
tion agent (Bio-Rad). Cell viability was assayed with
CellTiter-Blue (CTB) fluorometric cell viability assay
(Promega). 10 μl of CTB diluted with 10 μlo fO p t i -
MEM 1 (Gibco) medium without supplements was
added to each 96-well containing 100 μlo fm e d i u m
and cells. Reagent was incubated at +37°C for 4 h fol-
lowed with 2 h stabilization at RT before analysis.
Fluorescence signal (Exitation 560 nm, Emission 590
nm) reflecting the relative number of viable cells per
well was measured with EnVision fluorescence plate
reader (PerkinElmer). Data of four replicate wells was
combined for analysis.
Additional material
Additional file 1: Supplemental video 1. Timelapse microscopic
imaging of PC3 prostate cancer cells seeded on array with 200 μm spots
and imaged for 72 h. Images were collected using a x20 objective with
30 minute intervals.
Additional file 2: Supplemental Table 1. List of cell lines tested with
the CSMA method. 92 adherent cell types were tested for compatibility
with the CSMA cell patterning method. Four different cell dissociation
methods were tested in parallel and protocol allowing maximally
efficient cell patterning was optimized for all tested cell types.
Additional file 3: Supplemental figure S1. (A) Validation of CSMA
transfection efficacy in VCaP cells was performed using four different siRNA
constructs for CAPN2 and a control siRNA. Composite (CAPN2 = red, DNA =
blue) and single channel confocal laser microarray scanned images of a
VCaP array with four 24 replicate spot sub-grids of three CAPN2 and control
siRNA constructs. Scale bar 900 μm. (B) 20× microscopic images of control
siRNA and CAPN2 siRNA spots with an intensity surface plot visualization of
the intra-spot signal distribution of anti-CAPN2 staining (lower panels). (C)
Upper panel: On basis of the immunofluorescent detection of CAPN2 an up
to 94% spot level efficacy was measured with spot level normalization
against DNA counterstaining of the cells. The mean efficacy of CAPN2
siRNAs varied from 31% to 94% silencing. Lower panel: Comparative
Western blot analysis of cells transfected using conventional methods
provided identical efficacy profiles for the siRNA constructs. (D) Western blot
of analysis of cells recovered from a CSMA array of 384 replicate CAPN2 and
control siRNA spots after 72 h transfection was used to validate the
transfection efficacy in VCaP and PC-3 prostate cancer cells and SVpgC2a
oral keratinocytes.
Additional file 4: Supplemental data 1. Results summary table listing
the CSMA results of the functional analysis of the GPCR targeting siRNAs.
Additional file 5: Supplemental figure S2. Tissue level unsupervised
hierarchical clustering of the 7 candidate primary RNAi hit genes
identified with an increased expression pattern in clinical prostate
samples. Each cell in the cluster shows the log2 expression ratio for the
particular gene in separate tissue samples divided by the median
expression of that gene in all the samples. Red; expression above the
median, blue; below the median.
Additional file 6: Supplemental data 2. Table listing the
transcriptomics analysis results of the analysed genes in the Genesapiens
transcriptomics database. Genes represented with a minimum of 10
analyzed healthy and cancer tissue samples were included.
Additional file 7: Supplemental figure S3. Box plot graphs displaying
normalized expression levels of GPR160 and NPY across major tissue
groups divided into healthy and cancer samples in the Genesapiens
transcriptomics database.
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Page 12 of 14Additional file 8: Supplemental figure S4. (A) Representative
immunohistochemistry staining of tissue microarray cores of healthy and
prostate cancer samples for GPR160 http://www.proteinatlas.org. (B)
Knockdown performance of siRNAs targeting GPR160 and NPY. Transcript
levels for duplicate experiments with triplicate samples were measured
by quantitative RT-PCR and are reported for each siRNA in the increasing
efficacy order relative to average transcript levels for negative control
siRNA transfections.
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